Page last updated: 2024-11-09

ethionamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2761171
CHEMBL ID1441
CHEBI ID4885
SCHEMBL ID27007
MeSH IDM0007869

Synonyms (246)

Synonym
AC-13715
ethionamide [usan:usp:inn:ban:jan]
5-22-02-00360 (beilstein handbook reference)
oay8ors3cq ,
unii-oay8ors3cq
MLS001074114
AB00051990-09
BRD-K33710385-001-05-4
amidazine
ethyonomide
2-ethyl-4-pyridinecarbothioamide
etiocidan
iridocin
etionizin
thiomid
1314 tn
wln: t6nj b2 dyzus
2-ethylthioisonicotinamide
trescatyl
etionid
amidazin
nisotin
fatoliamid
.alpha.-ethylisonicotinoylthioamide
aetiva
etionizine
tiomid
teberus
nicotion
tianid
atina
tuberoson
itiocide
isonicotinamide, 2-ethylthio-
tubermin
.alpha.-ethylisonicotinic acid thioamide
tuberoid
2-ethyl-4-thiocarbamoylpyridine
.alpha.-ethylisothionicotinamide
trecator
etionamid
2-ethyl-4-thioamidylpyridine
ethinamide
iridocin bayer
nsc-255115
thianid
f.i. 58-30
ethylisothiamide
bayer 5312
isothin
tubenamide
aetina
etionizina
thianide
sertinon
1314th
rigenicid
trekator
ethioniamide
.alpha.-ethylthioisonicotinamide
2-ethylisothionicotinamide
ethimide
ethionamid prothionamid
2-ethylisonicotinic acid thioamide
trescazide
nizotin
iridozin
2-ethylisonicotinic thioamide
thioniden
etioniamid
2-ethylisonicotinothioamide
ethina
nci-c01694
isotiamida
KBIO1_000145
DIVK1C_000145
smr000058716
MLS000069764 ,
etimid
SPECTRUM_001082
PRESTWICK3_000526
SPECTRUM5_000979
PRESTWICK_842
NCGC00016497-01
cas-536-33-4
BSPBIO_000511
BPBIO1_000563
CHEBI:4885 ,
ethionamidum
etionamida
etionamide
trecator sc
thioamide
nsc255115
2-ethylpyridine-4-carbothioamide
1314 th
.alpha.-ethyl-thioisonicotinamide
trecator-sc
th 1314
4-pyridinecarbothioamide, 2-ethyl-
bayer5312
BSPBIO_002016
PRESTWICK2_000526
ETP ,
NCGC00091074-01
AB00051990
ccris 287
nsc 255115
einecs 208-628-9
alpha-ethylisothionicotinamide
alpha-ethylisonicotinoylthioamide
alpha-ethylthioisonicotinamide
etionamida [inn-spanish]
2-ethylisonicotinic acid thiomide
brn 0116474
3-ethylisothionicotinamide
ethionamidum [inn-latin]
tio-mid
isonicotinimidic acid, 2-ethylthio-
1314-th
hsdb 7473
etionamide [dcit]
ethina (van)
alpha-ethylisonicotinic acid thioamide
aethionamidum
ethionamide
C07665
536-33-4
2-ethyl-4-thiopyridylamide
DB00609
ethionamide (jp17/usp/inn)
trecator (tn)
D00591
IDI1_000145
NCGC00091074-03
NCGC00091074-02
NCGC00091074-04
KBIO2_006698
KBIO2_001562
KBIOSS_001562
KBIOGR_001213
KBIO3_001236
KBIO2_004130
PRESTWICK1_000526
PRESTWICK0_000526
SPECTRUM2_000994
NINDS_000145
SPBIO_001087
SPBIO_002432
SPECTRUM3_000428
SPECTRUM4_000547
SPECTRUM1500292
HMS2091F03
CHEMBL1441
smr001370750
MLS002454402
HMS500H07
inchi=1/c8h10n2s/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5h,2h2,1h3,(h2,9,11)
aeocxxjpgcbfja-uhfffaoysa-
e0695 ,
HMS1920M22
HMS1569J13
cpd001370750
NCGC00016497-05
HMS3259K17
HMS2096J13
dtxcid00577
tox21_302769
NCGC00256600-01
dtxsid0020577 ,
tox21_202409
NCGC00259958-01
A829694
2-ethylpyridine-4-carbothioamide;ethionamide
AKOS006220662
nsc757028
nsc-757028
pharmakon1600-01500292
tox21_110458
2-ethyl-thioisonicotinamide
HMS2231F10
HMS2233J11
CCG-40212
NCGC00016497-02
NCGC00016497-03
NCGC00016497-06
NCGC00016497-04
NCGC00016497-08
FS-1770
ethionamide [who-ip]
ethionamide [jan]
ethionamide [ep monograph]
ethionamide [usan]
ethionamide [usp-rs]
ethionamide [hsdb]
ethionamide [iarc]
ethionamide [mart.]
ethionamide [usp monograph]
ethionamide [orange book]
ethionamide [mi]
ethionamide [vandf]
ethionamidum [who-ip latin]
ethionamide [who-dd]
ethionamide [inn]
S1777
HMS3371D12
HMS3370I18
HY-B0276
NC00508
SCHEMBL27007
tox21_110458_1
NCGC00016497-09
mfcd00057361
2-ethylisonicotinothiamide
thiodine
isonicotinamide, 2-ethyl, thio-
2-ethylisonicotinthioamide
W-105719
AB00051990_10
AB00051990_11
OPERA_ID_632
SR-01000759219-5
sr-01000759219
SR-01000759219-2
ethionamide, united states pharmacopeia (usp) reference standard
ethionamide, european pharmacopoeia (ep) reference standard
HMS3655M10
ethionamide for system suitability, european pharmacopoeia (ep) reference standard
SBI-0051377.P003
HMS3713J13
SW196973-3
Q414767
F15438
BRD-K51207550-001-09-9
trecator;2-ethylthioisonicotinamide;ethinamide; ethioniamide; trecator sc; trecator-sc
BCP29626
ethinamide; 2-ethylthioisonicotinamide; 2-ethylpyridine-4-carbothioamide
ethionamide for system suitability
EN300-7475922
ethionamide (iarc)
j04ad03
ethionamide (usp-rs)
2-ethyl-4-pyridine-carbothioamide
ethionamide (mart.)
ethionamide (ep monograph)
ethionamide (usp monograph)

Research Excerpts

Overview

Ethionamide is a structural analogue of isoniazid and the two drugs share other similarities, including their metabolism, therapeutic targets, hepato-toxicity patterns and drug resistance. It is an important contributor to MDR-TB treatment regimens, at Sensititre MIC <2.5 mg/L.

ExcerptReferenceRelevance
"Ethionamide is a key antibiotic prodrug of the second-line chemotherapy regimen to treat tuberculosis. "( Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
Baulard, AR; Bourotte, M; Déprez, B; Frita, R; Prieri, M; Probst, N; Sournia-Saquet, A; Willand, N, 2018
)
2.22
"Ethionamide (ETH) is a commercial drug, used as a second-line resource to neutralize "( New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.
Alves, C; Correia, A; Duarte, D; Figueiredo, P; Santos, HA; Vale, N, 2020
)
2.33
"Ethionamide (ETH) is a high-profile drug for the treatment of patients with multidrug-resistant "( New ethionamide boosters and EthR2: structural and energetic analysis.
Barbosa, ED; Bezerra, KS; Freire, VN; Fulco, UL; Lima Costa, AH; Lima Neto, JX; Oliveira, JIN; Vianna, JF, 2021
)
2.62
"Ethionamide (ETH) is a second line antitubercular drug suffering from poor solubility in water and strong tendency to crystallize. "( Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization.
Benkovics, G; Fenyvesi, E; Gref, R; Malanga, M; Manet, I; Manoli, F; Pancani, E; Salzano, G; Wankar, J, 2017
)
2.22
"Ethionamide is an anti-tuberculous drug frequently used to treat MDR-TB."( Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in
Farooqi, JQ; Hasan, R; Jabeen, K; Qamar, S,
)
1.09
"Ethionamide is an important contributor to MDR-TB treatment regimens, at Sensititre MIC <2.5 mg/L. "( Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Bendet, P; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S, 2018
)
3.37
"Ethionamide is a structural analogue of isoniazid and the two drugs share other similarities, including their metabolism, therapeutic targets, hepato-toxicity patterns and drug resistance."( Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases.
Dheda, K; Dlamini, S; Gantsho, N; Lehloenya, RJ; Muloiwa, R; Todd, G, 2015
)
1.4
"Ethionamide (ETH) is an antibiotic used for the treatment of multidrug-resistant (MDR) tuberculosis (TB) (MDR-TB), and its use may be limited with the emergence of resistance in the Mycobacterium tuberculosis population. "( Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Ferro, BE; Mejia, GI; Realpe, T; Robledo, J; Rozo, JC; Rueda, J; Zapata, E, 2015
)
2.07
"Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium tuberculosis. "( Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Correia, A; Figueiredo, P; Fraga, A; Hirvonen, J; Mäkilä, E; Pedrosa, J; Salonen, J; Santos, HA; Silva, S; Vale, N, 2017
)
2.16
"Ethionamide (ETH) is a structural analogue of isoniazid (INH). "( Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
Brittle, W; Donald, PR; Hesseling, AC; Jordaan, AM; Marais, BJ; Schaaf, HS; van Helden, PD; Venter, A; Victor, TC, 2009
)
3.24
"Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. "( Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.
Böttger, EC; Burri, R; Fussenegger, M; Gitzinger, M; Grau, T; Sander, P; Selchow, P; Tigges, M, 2012
)
1.82
"Ethionamide (ETA) is a thioamide antibiotic and one of the most widely used drugs as second line agent for the treatment of MDR-TB."( New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Gomes, P; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Vale, N, 2012
)
1.4
"Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium. "( Metabolism of the antituberculosis drug ethionamide.
Gomes, P; Santos, HA; Vale, N, 2013
)
2.1
"Ethionamide (ETH) is a structural analog of the antituberculosis drug isoniazid (INH). "( ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates.
Cooksey, RC; Crawford, JT; Metchock, B; Morlock, GP; Sikes, D, 2003
)
2.05
"Ethionamide (ETH) is an important second-line antitubercular drug used for the treatment of patients infected with multidrug-resistant Mycobacterium tuberculosis. "( EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
Aumercier, M; Baillat, D; Baulard, AR; Bellefontaine, F; Besra, GS; Engohang-Ndong, J; Locht, C, 2004
)
2.01
"Ethionamide appears to be a potential goitrogen in susceptible persons."( Ethionamide-induced goitrous hypothyroidism.
Burrow, GN; Drucker, D; Eggo, MC; Salit, IE, 1984
)
2.43
"Ethionamide (ETA) is an important component of second-line therapy for the treatment of multidrug-resistant tuberculosis. "( Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.
Barry, CE; Bekker, LG; Bosman, M; DeBarber, AE; Mdluli, K, 2000
)
3.19

Effects

ExcerptReferenceRelevance
"Ethionamide has been used for more than 30 years as a second-line chemotherapeutic to treat tuberculosis patients who have developed resistance to first-line drugs, such as isoniazid (INH) and rifampicin. "( Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance.
Besra, GS; Cocklin, SL; Corsino, PE; Daniels, IR; Dover, LG; Fütterer, K; Tatituri, V, 2004
)
1.98

Treatment

ExcerptReferenceRelevance
"Ethionamide (ETH) treatment may cause hypothyroidism. "( Abnormal thyroid function tests in children on ethionamide treatment.
Hesseling, AC; Magdorf, K; Schaaf, HS; Thee, S; Willemse, M; Zöllner, EW, 2011
)
2.07

Toxicity

ExcerptReferenceRelevance
"The role of S-oxidation in the toxic bioactivation of alpha-naphthylisothiocyanate (ANIT) was investigated."( Effect of inhibitors of alpha-naphthylisothiocyanate-induced hepatotoxicity on the in vitro metabolism of alpha-naphthylisothiocyanate.
Hanzlik, RP; Traiger, GJ; Vyas, KP, 1985
)
0.27
" Thus, this study shows that agents which sensitize or protect rats from the toxic effects of ANIT, correspondingly stimulate or inhibit the oxidative desulfuration of [35S]ANIT in vivo."( Effect of thiocarbonyl compounds on alpha-naphthylisothiocyanate-induced hepatotoxicity and the urinary excretion of [35S]alpha-naphthylisothiocyanate in the rat.
Hanzlik, RP; Traiger, GJ; Vyas, KP, 1984
)
0.27
" It is concluded that the combination RMP + ETH is the toxic component."( Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.
Bourland, J; Davies, EM; Feracci, C; Grillone, S; Janssens, L; Pattyn, SR; Saylan, T, 1984
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Among 69 patients with drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) to FLDs, FLDs were stopped and SLDs added when the skin and laboratory parameters had settled."( Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases.
Dheda, K; Dlamini, S; Gantsho, N; Lehloenya, RJ; Muloiwa, R; Todd, G, 2015
)
0.68
" Adverse events associated with second-line drugs (SLDs) can have severe impact on efficient management."( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016
)
0.43
"To know the frequency of adverse events due to SLDs in patients of MDR-TB."( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016
)
0.43
" Adverse events associated with treatment were recognized primarily by clinical evidence and/or laboratory investigations that were advised at baseline and whenever clinically indicated during course of treatment."( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016
)
0.43
"119 adverse events were reported in 46 (46."( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016
)
0.43
"MDR-TB can be cured successfully with appropriate combination of drugs if adverse events associated with them can be managed aggressively and timely."( Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016
)
0.43

Pharmacokinetics

This study was conducted in order to determine the effect of food, orange juice, or antacids on the absorption of a single oral 500-mg dose of ethionamide (ETA) Ethionamide-loaded PLGA nanoparticles exhibited significant improvement in pharmacokinetic parameters.

ExcerptReferenceRelevance
"This study was conducted in order to (i) determine the effect of food, orange juice, or antacids on the absorption of a single oral 500-mg dose of ethionamide (ETA) in healthy volunteers, including an assessment of bioequivalence, and (ii) determine ETA population pharmacokinetic (PK) parameters."( Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.
Adam, RD; Auclair, B; James, GT; Nix, DE; Peloquin, CA, 2001
)
0.83
"To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
" No other statistically significant differences were observed for Cmax and area under the curve from time zero to infinity across the four treatments."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
"Determine the population pharmacokinetic (PK) parameters of ethionamide (ETA) following multiple oral doses."( Population pharmacokinetics of ethionamide in patients with tuberculosis.
Berning, SE; Bulpitt, AE; Namdar, R; Peloquin, CA; Stambaugh, JJ; Starke, JR; Zhu, M, 2002
)
0.84
" ETA displayed a short elimination half-life (1."( Population pharmacokinetics of ethionamide in patients with tuberculosis.
Berning, SE; Bulpitt, AE; Namdar, R; Peloquin, CA; Stambaugh, JJ; Starke, JR; Zhu, M, 2002
)
0.6
" The developed assay was applied to a pharmacokinetic study in humans."( Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of ethionamide and ethionamide sulfoxide in human plasma: application to a human pharmacokinetic study.
Deshpande, AY; Gurav, S; Kulkarni, R; Mullangi, R; Mungantiwar, A; Pandey, S; Punde, R; Zambre, V, 2011
)
0.59
" The aim of this study was to determine the pharmacokinetic parameters for ETH in children on antituberculosis treatment including ETH."( Pharmacokinetics of ethionamide in children.
Donald, PR; Hesseling, AC; Magdorf, K; Rosenkranz, B; Schaaf, HS; Seifart, HI; Thee, S, 2011
)
0.69
" Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required."( Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
Baulard, AR; Blondiaux, N; Brodin, P; Christophe, T; Déprez, B; Desroses, M; Flament, MP; Flipo, M; Jeon, HK; Lecat-Guillet, N; Leroux, F; Locht, C; Mathys, V; Piveteau, C; Siepmann, J; Soror, SH; Villemagne, B; Villeret, V; Willand, N; Wintjens, R; Wohlkönig, A, 2012
)
1.82
" ETH appearance in plasma, bronchoalveolar lavage, and lung tissues was measured and subjected to noncompartmental pharmacokinetic analysis."( Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Edwards, D; Elbert, K; Garcia-Contreras, L; Hickey, A; Muttil, P; Padilla-Carlin, DJ; Peloquin, C; Sung, J; VerBerkmoes, J, 2017
)
0.78
" To test this hypothesis, a full physiologically based pharmacokinetic (PBPK) model of ethionamide was established and validated in adults through incorporation of comprehensive metabolism and transporter profiles, then expanded to the pediatric population through integration of FMO3 maturational changes over time."( Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavin-Containing Monooxygenase 3 Maturational Changes Over Time.
Ahn, S; Ghim, JL; Ho Lee, J; Kim, MJ; Nguyen, PTT; Parvez, MM; Shin, JG, 2018
)
0.94
" The drug-drug interaction leading to methimazole affecting the disposition of ethionamide mediated by FMO3 was then quantitated using a bottom-up approach with a physiologically based pharmacokinetic framework."( Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3.
Ahn, S; Ghim, JL; Kim, MJ; Nguyen, PTT; Parvez, MM; Shin, JG; Yoo, SE, 2019
)
0.96
" It is important to generate pharmacokinetic studies of drugs used to treat MDR TB in children in different settings, which would provide useful information on the adequacy of drug doses."( Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
Ramachandran, G, 2019
)
0.51

Compound-Compound Interactions

Sparfloxacin was used in combination with kanamycin (for the initial 3-4 months) and ethionamide, in multidrug-resistant (MDR) pulmonary tuberculosis patients.

ExcerptReferenceRelevance
"5 micrograms/ml dapsone significantly inhibited growth of MAC bacteria when used in combination with other drugs specifically acting at the mycobacterial cell-wall level."( Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.
Goh, KS; Labrousse, V; Rastogi, N, 1993
)
0.29
"To study the efficacy and safety of sparfloxacin, in combination with kanamycin (for the initial 3-4 months) and ethionamide, in multidrug-resistant (MDR) pulmonary tuberculosis patients."( Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Arora, VK; Gupta, R; Gupta, S; Singla, R, 2001
)
0.76
" Ultimately, the good permeability, moderate rates of metabolism and low risk of drug-drug interactions displayed by some of the synthesized compounds indicate that 2-(quinolin-4-yloxy)acetamides may yield candidates to use in the development of novel alternative therapeutics for tuberculosis treatment."( New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
Abbadi, BL; Back, DF; Basso, LA; Campos, MM; Giacobbo, BC; Grams, ES; Machado, P; Pissinate, K; Rodrigues-Junior, V; Santos, DS; Sperotto, N; Subtil, FT; Trindade, RV; Villela, AD, 2017
)
0.46
" The drug-drug interaction leading to methimazole affecting the disposition of ethionamide mediated by FMO3 was then quantitated using a bottom-up approach with a physiologically based pharmacokinetic framework."( Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3.
Ahn, S; Ghim, JL; Kim, MJ; Nguyen, PTT; Parvez, MM; Shin, JG; Yoo, SE, 2019
)
0.96

Bioavailability

ExcerptReferenceRelevance
" The area under the serum concentration-time curve was used to compare the relative bioavailability of ETA from the two preparations."( Pharmacokinetic evaluation of ethionamide suppositories.
Goble, M; James, GT; McCarthy, E; Peloquin, CA, 1991
)
0.57
" The investigations--in most cases estimations of the nonbiotransformated part of antituberculotic drugs and theophylline had following purposes: security of the necessary dose especially in the case of INH (hereditary INH-polymorphismus), proof of a sufficient permeation of INH and RMP in the tuberculous kidney, control of the usefulness or uselessness of the INH-depot-preparations, relations between the concentration in the serum and dose respectively of the appearance of side effects, estimation of bioavailability and pharmacokinetic parameters during the development of an useful retard-preparation of theophylline."( [Clinical pharmacology in optimization of therapy of lung diseases].
Iwainsky, H; Wiesner, B; Winsel, K, 1991
)
0.28
"1 h, where K(a) is the absorption rate constant, V is the volume of distribution, and CL is clearance."( Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.
Adam, RD; Auclair, B; James, GT; Nix, DE; Peloquin, CA, 2001
)
0.63
" This study was conducted to explore issues relating to bioavailability in the presence of food, orange juice, and antacid."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
" The pharmacokinetics of clofazimine were assessed using individual- and population-based methods and relative bioavailability compared to fasting administration was determined."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
"Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
" Over the years, some studies have emerged to improve the bioavailability of this drug and of its active metabolites."( New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Gomes, P; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Vale, N, 2012
)
0.68
"The study objective was to compare the bioavailability of the film-coated (test) and sugar-coated (reference) formulations of ethionamide."( Comparative bioavailability study of single-dose film-coated and sugar-coated ethionamide tablets in healthy volunteers.
Korth-Bradley, JM; Mansfield, D; Mayer, P; Tucker, H; Wu, D, 2014
)
0.84
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Ethionamide (ETH), a Biopharmaceutics Classification System class II drug, is a second-line drug manufactured as an oral dosage form by Pfizer.

ExcerptRelevanceReference
" But this effect is small and does not justify a change in the usual dosage of rifampicin."( [The use of mycobacteria in the estimation of the concentration of antibiotics, antimycotics and antituberculotics (author's transl)].
Iwainsky, H; Reutgen, H; Sesser, I, 1978
)
0.26
" Basing their comment on the published literature, they analyze the properties, pharmacology, toxicity, and side-effects of each medication, and define their dosage and modes of administration."( [Principles underlying the use of antituberculosis medication in children (author's transl)].
Besson-Leaud, M; Ollivier, A,
)
0.13
" ENL was also more frequent in regimens C and D and was not prevented by CLO in the dosage used."( Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Coussens, L; Groenen, G; Janssens, L; Kayembe, T; Nollet, E; Pattyn, SR, 1986
)
0.27
"The blood levels and urinary excretion of the anti-mycobacterial drugs ethionamide and prothionamide have been compared after oral dosage in man."( A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man.
Aber, VR; Ellard, GA; Gruer, PJ; Jenner, PJ, 1984
)
0.74
"A prospective, observational study of isoniazid (INH), rifampicin (RMP) and ethionamide (ETH) in a dosage of 20 mg/kg, and pyrazinamide (PZA) 40 mg/kg, all given once daily in hospital for 6 months."( Intensive short course chemotherapy in the management of tuberculous meningitis.
De Villiers, JN; Donald, PR; Pretorius, M; Schoeman, JF; Springer, P; Van Zyl, LE, 1998
)
0.53
" CS is significantly removed by hemodialysis and should be dosed after hemodialysis."( The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Childs, JM; Fish, DN; Malone, RS; Peloquin, CA; Spiegel, DM, 1999
)
0.57
" The effect of different dosing strategies on calculated pharmacodynamic parameters was explored."( Population pharmacokinetics of ethionamide in patients with tuberculosis.
Berning, SE; Bulpitt, AE; Namdar, R; Peloquin, CA; Stambaugh, JJ; Starke, JR; Zhu, M, 2002
)
0.6
" Additional research is needed to determine the optimal dosing of ETA."( Population pharmacokinetics of ethionamide in patients with tuberculosis.
Berning, SE; Bulpitt, AE; Namdar, R; Peloquin, CA; Stambaugh, JJ; Starke, JR; Zhu, M, 2002
)
0.6
" The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time."( Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
Barrera, L; de Kantor, IN, 2007
)
0.34
"Sustained release nanoformulations of second line anti-tubercular drugs can help in reducing their dosing frequency and improve patient's compliance in multi-drug resistant tuberculosis (MDR TB)."( Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Khuller, GK; Kumar, G; Malhotra, S; Pandhi, P; Shafiq, N; Sharma, S, 2011
)
0.59
"Ethionamide (ETH), a Biopharmaceutics Classification System class II drug, is a second-line drug manufactured as an oral dosage form by Pfizer to treat tuberculosis."( Mechanochemistry applied to reformulation and scale-up production of Ethionamide: Salt selection and solubility enhancement.
da Silva, CC; de Melo, CC; Ellena, J; Pereira, CC; Rosa, PC, 2016
)
2.11
" These ETH-conjugated NPs have great potential in reducing dosing frequency of ETH in the treatment of multidrug-resistant tuberculosis (MDR-TB)."( Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Correia, A; Figueiredo, P; Fraga, A; Hirvonen, J; Mäkilä, E; Pedrosa, J; Salonen, J; Santos, HA; Silva, S; Vale, N, 2017
)
0.72
"PLGA (50:50) nanoparticles were prepared to sustain the release of Ethionamide in order to decrease the dose and dosing frequency."( PLGA Ethionamide Nanoparticles for Pulmonary Delivery: Development and in vivo evaluation of dry powder inhaler.
Debnath, SK; Omri, A; Saisivam, S, 2017
)
1.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antitubercular agentA substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
fatty acid synthesis inhibitorAny pathway inhibitor that inhibits the synthesis of fatty acids.
leprostatic drugA substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
thiocarboxamideAny primary amide having its amide oxygen replaced by sulfur.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ethionamide activation014

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency24.33650.000714.592883.7951AID1259369
Smad3Homo sapiens (human)Potency0.11220.00527.809829.0929AID588855
EWS/FLI fusion proteinHomo sapiens (human)Potency20.93100.001310.157742.8575AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency25.11890.000214.376460.0339AID588532
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency44.28460.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.92820.000229.305416,493.5996AID743075; AID743077; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.32820.001024.504861.6448AID743212
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.097719.739145.978464.9432AID1159509
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
DNA polymerase betaHomo sapiens (human)Potency63.09570.022421.010289.1251AID485314
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.16830.000627.21521,122.0200AID743202; AID743219
Nuclear receptor ROR-gammaHomo sapiens (human)Potency1.18830.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)4.00000.03403.987110.0000AID1265266
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKic1.90000.70002.30004.3000AID1265268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (210)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID576916Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2858c Aldc gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID576922Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2671 RibD gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1181176Antimicrobial activity against Mycobacterium tuberculosis H37Rv over-expressing InhA cells assessed as upshift of MIC relative to wild type2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID283669Antimycobacterial activity against Mycobacterium bovis BCG Pasteur with pMV261 vector2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID574809Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1422278Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Rv after 7 days in presence of EthR inhibitor BDM41906 by fluorescence assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID1883681Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID576910Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0155 PntAA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID562239Antimycobacterial activity against Mycobacterium smegmatis by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID713897Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID576920Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2971 probable oxidoreductase gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID569412Antimycobacterial activity against Mycobacterium bovis BCG carrying pMV2612011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1378014Antimycobacterial activity against Mycobacterium tuberculosis MC2 62302017European journal of medicinal chemistry, Sep-29, Volume: 138Triazole derivatives and their anti-tubercular activity.
AID374316Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-33 mutant expressing VV16 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1585696Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1557257Antitubercular activity against resistant Mycobacterium tuberculosis harboring ethA mutant incubated for 9 days by microplate alamar blue assay2019MedChemComm, Aug-01, Volume: 10, Issue:8
Drug-resistance in
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1784361Antimycobacterial activity against Mycobacterium tuberculosis InhA-OE overexpressing H37Rv-LP:fabGl/inhA-c-15t in presence of middlebrook 7H9/glucose/BSA/tyloxapol medium measured for 2 weeks by bioluminescence reporter assay2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in
AID283671Antimycobacterial activity against Mycobacterium bovis BCG str. Pasteur 1173P2 overexpressing ethA gene2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID374313Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv expressing VV16 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1422281Ratio of MIC50 for GFP expressing Mycobacterium tuberculosis H37Rv in absence of EthR2 inhibitor SMARt-420 to MIC50 for GFP expressing Mycobacterium tuberculosis H37Rv in presence of EthR2 inhibitor SMARt-4202018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID1422279Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Rv after 7 days in presence of EthR2 inhibitor SMARt-420 by fluorescence assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID283663Antimycobacterial activity against Mycobacterium bovis BCG NCTC 56922007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID283664Antimycobacterial activity against Mycobacterium bovis BCG NCTC 5692 with ethR-knockout mutant2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID574811Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID576905Antimicrobial activity against Mycobacterium smegmatis MC2 5089 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1484 InhA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1422282Electrochemical behavior of the compound assessed as redox potential corrected toward normal hydrogen electrode at 10'-3 M by cyclic voltammetry2018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1422280Ratio of MIC50 for GFP expressing Mycobacterium tuberculosis H37Rv in absence of EthR inhibitor BDM41906 to MIC50 for GFP expressing Mycobacterium tuberculosis H37Rv in presence of EthR inhibitor BDM419062018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID251786Antimycobacterial activity of compound against Mycobacterium tuberculosis H37Rv at 2.50 ug/mL2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Antituberculous activity of some aryl semicarbazone derivatives.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1784362Antimycobacterial activity against Mycobacterium tuberculosis KatG T198A in presence of middlebrook 7H9/glucose/BSA/tyloxapol medium measured for 2 weeks by bioluminescence reporter assay2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in
AID355266Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth microdilution method1997Journal of natural products, Dec, Volume: 60, Issue:12
Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity.
AID562238Antimycobacterial activity against Mycobacterium smegmatis assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID574808Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1435844Antimycobacterial activity against Mycobacterium tuberculosis CDCT-4 (1105/09) clinical isolate after 7 days by resazurin reduction microplate assay2017European journal of medicinal chemistry, Jan-27, Volume: 126New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID576909Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1187 RocA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1883742Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID565231Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1422277Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Rv after 7 days by fluorescence assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
AID1653417Inhibition of PGL1 synthesis in Mycobacterium leprae infected Swiss Webster mouse macrophages assessed as decrease in [U-14C]PA incorporation at 2 uM preincubated for 4 days post infection followed by [U-14C]PA addition and measured after 7 days by liquid2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1378013Antimycobacterial activity against Mycobacterium tuberculosis MC2 70002017European journal of medicinal chemistry, Sep-29, Volume: 138Triazole derivatives and their anti-tubercular activity.
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1695726Drug metabolism in human HepG2 cells assessed as formation of 2-ethylpyridine-4-carbonitrile at 0.1 to 2 mM measured after 3 to 48 hrs in presence of methionine by LC-MS/MS analysis2020RSC medicinal chemistry, Dec-17, Volume: 11, Issue:12
New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.
AID1265268Non-competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1695727Acid dissociation constant, pKa of the compound2020RSC medicinal chemistry, Dec-17, Volume: 11, Issue:12
New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.
AID1916612Antitubercular activity against Mycobacterium tuberculosis mc 2 7000 assessed as bacterial growth inhibition2022European journal of medicinal chemistry, Aug-05, Volume: 238Emerging impact of triazoles as anti-tubercular agent.
AID534419Antibacterial activity against Mycobacterium bovis BCG-Connaught2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
AID576915Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0091 Mtn/Sah gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID574806Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID576912Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1996 universal stress protein gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID576913Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0468 FadB2 gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID574810Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283670Antimycobacterial activity against Mycobacterium bovis BCG str. Pasteur 1173P2 overexpressing ethR gene2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID576921Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2766 FabG5 gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID576914Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2691 CeoB/TrKA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID649473Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by MTT assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Anti-mycobacterial activities of some cationic and anionic calix[4]arene derivatives.
AID1653418Inhibition of PGL1 synthesis in Mycobacterium leprae infected Swiss Webster mouse macrophages assessed as decrease in [U-14C]PA incorporation at 20 uM preincubated for 4 days post infection followed by [U-14C]PA addition and measured after 7 days by liqui2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID565230Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID576904Antimicrobial activity against Mycobacterium smegmatis MC2 4517 by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1435842Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin reduction microplate assay2017European journal of medicinal chemistry, Jan-27, Volume: 126New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1435843Antimycobacterial activity against Mycobacterium tuberculosis PE-003 clinical isolate after 7 days by resazurin reduction microplate assay2017European journal of medicinal chemistry, Jan-27, Volume: 126New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID576919Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv3777 probable oxidoreductase gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID574807Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID576917Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv1059 unknown gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1883741Antibacterial activity against extensively drug-resistant Mycobacterium tuberculosis clinical isolate assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID576911Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2623 universal stress protein gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID576906Antimicrobial activity against Mycobacterium smegmatis MC2 5097 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv2763c DfrA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID576907Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv3248c SahH gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID569413Antimycobacterial activity against Mycobacterium bovis BCG carrying pMV261::ethA2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1889501Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID569414Antimycobacterial activity against Mycobacterium bovis BCG carrying pMV261::ethR2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID576918Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0926c unknown gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1739636Antimycobacterial activity activity against GFP-tagged Mycobacterium tuberculosis H37Rv assessed as inhibition of microbial growth incubated for 5 days by fluorescence assay2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID565229Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID374314Antimycobacterial activity against wild-type Mycobacterium tuberculosis Mt103 expressing VV16 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID565228Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID374315Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-22 mutant expressing VV16 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1784353Antimycobacterial activity against Mycobacterium tuberculosis H37RvMA in presence of middlebrook 7H9/glucose/BSA/tyloxapol medium measured for 2 weeks by bioluminescence reporter assay2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in
AID283665Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG NCTC 5692 with ethR-knockout mutant assessed as incorporation of [2-14C]acetate2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID1889500Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2022Bioorganic & medicinal chemistry letters, 03-15, Volume: 60Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents.
AID576908Antimicrobial activity against Mycobacterium smegmatis MC2 4517 harboring pYUB1062 plasmid overexpressing Mycobacterium tuberculosis Rv0753c MmsA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,236)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990932 (75.40)18.7374
1990's41 (3.32)18.2507
2000's76 (6.15)29.6817
2010's144 (11.65)24.3611
2020's43 (3.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.89 (24.57)
Research Supply Index7.27 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index92.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (3.85%)5.53%
Reviews69 (5.01%)6.00%
Case Studies53 (3.85%)4.05%
Observational5 (0.36%)0.25%
Other1,196 (86.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]800 participants (Anticipated)Observational [Patient Registry]2018-07-01Recruiting
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in [NCT00000796]525 participants InterventionalCompleted
A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis [NCT05473195]Phase 2105 participants (Anticipated)Interventional2022-12-06Recruiting
Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial [NCT02454205]Phase 2/Phase 3154 participants (Actual)Interventional2015-11-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

[back to top]

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

[back to top]

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

[back to top]

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

[back to top]

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

[back to top]

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

[back to top]

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

[back to top]

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

[back to top]

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

[back to top]